Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2

Cruz, Roberto Alejandro; Hogan, Nick; Sconzert, Jayne; Sconzert, Megan; Major, Eugene O.; Lisak, Robert P.; Melamed, Esther; Varkey, Thomas; Meltzer, Ethan; Goodman, Andrew; Komogortsev, Oleg V.; Parsons, Matthew S.; Costello, Kathleen; Graves, Jennifer; Newsome, Scott D.; Zamvil, Scott S.; Frohman, Elliot M.; Frohman, Teresa C.

doi:10.1212/nxi.0000000000000930

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional reports include use of teriflunomide, rituximab, and alemtuzumab. [14][15][16] No patient developed recurrent PML, but this has been reported in patients with HIV despite immune recovery. 17 DMT may be safe after natalizumabassociated PML, although conclusions are limited by selection bias and follow-up duration.…”

Section: Discussionmentioning

confidence: 99%

Escalation to Anti-CD20 Treatment for Multiple Sclerosis Following Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Wolf,

Corboy

2024

Neur Clin Pract

View full text Add to dashboard Cite

ObjectivesDisease-modifying therapy (DMT) for multiple sclerosis (MS) after natalizumabassociated progressive multifocal leukoencephalopathy (PML) is controversial due to concern for recurrent PML. We describe DMT utilization for over a decade in a patient with MS who survived PML. Methods Case report. ResultsA 36-year-old woman was diagnosed with MS in 2002 and treated with interferon beta-1a until 2006, when she transitioned to natalizumab due to relapses. She presented in 2012 with 2 months of progressive cognitive and gait concerns and was diagnosed with PML by positive CSF JC virus testing with concordant clinical and MRI findings. She was treated with plasma exchange and then corticosteroids for PML immune reconstitution inflammatory syndrome before starting glatiramer acetate for DMT. She transitioned to dimethyl fumarate in 2013 after MS activity on MRI with negative CSF JC virus testing. Owing to worsening footdrop consistent with progression, she transitioned to ocrelizumab in 2017 and then to ofatumumab in 2020 due to logistics of medication administration. There has been no clinicoradiographic or CSF evidence of recurrent PML. DiscussionDMT selection is challenging for patients with MS who survive PML. We used an escalation approach extending to ocrelizumab and ofatumumab due to MS progression. Anti-CD20 DMTs are a high-efficacy option post-PML. Classification of EvidenceThis provides Class IV evidence. It is a single observational study without controls.

show abstract